2
Clinical Trials associated with Pegfilgrastim biosimilar(Reliance Life Sciences Pvt Ltd.) / RecruitingNot Applicable A randomized, double-blind, two-treatment, single-period, parallel design study to compare the pharmacokinetics and pharmacodynamics (PK/PD) of R-TPR-029 (test pegfilgrastim) 6 mg/0.6 mL of Reliance Life Sciences Pvt. Ltd., India with Neulasta® (reference pegfilgrastim) of Amgen Europe BV, the Netherlands in healthy, adult, human subjects following subcutaneous administration under fasting condition.
/ Active, not recruitingPhase 3 Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-029/ Neulasta® (Neulastim®) when given subcutaneously in patients with Chemotherapy Induced Neutropenia.
100 Clinical Results associated with Pegfilgrastim biosimilar(Reliance Life Sciences Pvt Ltd.)
100 Translational Medicine associated with Pegfilgrastim biosimilar(Reliance Life Sciences Pvt Ltd.)
100 Patents (Medical) associated with Pegfilgrastim biosimilar(Reliance Life Sciences Pvt Ltd.)
100 Deals associated with Pegfilgrastim biosimilar(Reliance Life Sciences Pvt Ltd.)